$0
Carisma’s CT-0508 (HER2 CAR-Macrophage) Receives Fast Track Designation From the FDA
On Wednesday, September 22, Carisma announced (press release) that the FDA has granted Fast Track designation to CT-0508 (HER2-targeting CAR-Macrophage) for HER2-overexpressing solid tumors. Below, Celltelligence provides insights on how CT-0508 could benefit from Fast Track designation, while discussing the potential advantages of CAR-Macrophages (CAR-M).